Murphy Capital Management Inc. decreased its stake in shares of Allergan PLC. (NYSE:AGN) by 7.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,680 shares of the company’s stock after selling 300 shares during the period. Murphy Capital Management Inc.’s holdings in Allergan PLC. were worth $894,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the stock. Farmers & Merchants Investments Inc. increased its position in Allergan PLC. by 18.1% in the second quarter. Farmers & Merchants Investments Inc. now owns 34,348 shares of the company’s stock valued at $8,350,000 after buying an additional 5,275 shares during the last quarter. Rothschild Investment Corp IL increased its position in Allergan PLC. by 12.8% in the second quarter. Rothschild Investment Corp IL now owns 12,023 shares of the company’s stock valued at $2,923,000 after buying an additional 1,369 shares during the last quarter. Schmidt P J Investment Management Inc. increased its position in Allergan PLC. by 3.5% in the second quarter. Schmidt P J Investment Management Inc. now owns 11,124 shares of the company’s stock valued at $2,704,000 after buying an additional 381 shares during the last quarter. Manning & Napier Advisors LLC increased its position in Allergan PLC. by 50.5% in the second quarter. Manning & Napier Advisors LLC now owns 18,035 shares of the company’s stock valued at $4,384,000 after buying an additional 6,055 shares during the last quarter. Finally, Oakbrook Investments LLC increased its position in Allergan PLC. by 1,373.9% in the second quarter. Oakbrook Investments LLC now owns 20,973 shares of the company’s stock valued at $5,098,000 after buying an additional 19,550 shares during the last quarter. 83.63% of the stock is owned by hedge funds and other institutional investors.
Shares of Allergan PLC. (AGN) traded down 1.06% on Wednesday, hitting $227.99. 3,546,750 shares of the stock were exchanged. The company has a market cap of $76.22 billion, a PE ratio of 6.95 and a beta of 1.16. The company has a 50-day moving average price of $245.00 and a 200 day moving average price of $238.77. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the prior year, the firm posted $3.35 EPS. Allergan PLC.’s revenue for the quarter was up 8.8% on a year-over-year basis. Equities analysts forecast that Allergan PLC. will post $16.27 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be given a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a yield of 1.23%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio (DPR) is 9.95%.
TRADEMARK VIOLATION WARNING: “Allergan PLC. (AGN) Stake Reduced by Murphy Capital Management Inc.” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://stocknewstimes.com/2017/08/16/allergan-plc-agn-position-cut-by-murphy-capital-management-inc-updated.html.
Several research firms have recently issued reports on AGN. Argus reaffirmed a “buy” rating and set a $280.00 price target on shares of Allergan PLC. in a research note on Monday. UBS AG reaffirmed an “outperform” rating and set a $275.00 price target on shares of Allergan PLC. in a research note on Wednesday, August 9th. Deutsche Bank AG reissued a “buy” rating and set a $278.00 target price (up previously from $273.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. BidaskClub downgraded shares of Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Finally, Wells Fargo & Company reissued an “outperform” rating and set a $280.00 target price (up previously from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. Eight analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $275.49.
In related news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.36% of the company’s stock.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.
